Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
- PMID: 18824034
- DOI: 10.1016/j.plipres.2008.08.001
Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries and is considered the hepatic manifestation of metabolic syndrome. The hallmark of NAFLD is hepatic neutral lipid accumulation, mainly triacylglycerol, in the absence of significant ethanol consumption, viral infection or other specific etiologies. Hepatic lipid accumulation results from an imbalance between lipid availability (from circulating lipid uptake or de novo lipogenesis) and lipid disposal (via free fatty acid oxidation or triglyceride-rich lipoprotein secretion) and eventually triggers lipoperoxidative stress and hepatic injury. Each of these steps is altered in NAFLD, although to a different extent. Regulation of these pathways is complex and involves nuclear receptors, membrane transport proteins and cellular enzymes. We will review available data on different steps of hepatic lipid metabolism in NAFLD and recent advances in understanding molecular mechanisms underlying hepatic fat accumulation in these subjects.
Similar articles
-
Liver fat and lipid oxidation in humans.Liver Int. 2009 Oct;29(9):1439-46. doi: 10.1111/j.1478-3231.2009.02076.x. Epub 2009 Jul 7. Liver Int. 2009. PMID: 19602132
-
Hepatic lipid metabolism and non-alcoholic fatty liver disease.Nutr Metab Cardiovasc Dis. 2009 May;19(4):291-302. doi: 10.1016/j.numecd.2008.12.015. Epub 2009 Apr 8. Nutr Metab Cardiovasc Dis. 2009. PMID: 19359149 Review.
-
Abnormalities of lipid metabolism in nonalcoholic fatty liver disease.Semin Liver Dis. 2008 Nov;28(4):351-9. doi: 10.1055/s-0028-1091979. Epub 2008 Oct 27. Semin Liver Dis. 2008. PMID: 18956291 Review.
-
The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease.Int J Mol Med. 2008 Nov;22(5):663-7. Int J Mol Med. 2008. PMID: 18949388
-
A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels.Am J Physiol Endocrinol Metab. 2008 May;294(5):E969-77. doi: 10.1152/ajpendo.00497.2007. Epub 2008 Mar 18. Am J Physiol Endocrinol Metab. 2008. PMID: 18349115
Cited by
-
Ficolin 3 promotes ferroptosis in HCC by downregulating IR/SREBP axis-mediated MUFA synthesis.J Exp Clin Cancer Res. 2024 May 3;43(1):133. doi: 10.1186/s13046-024-03047-2. J Exp Clin Cancer Res. 2024. PMID: 38698462 Free PMC article.
-
Afriplex GRTTM extract attenuates hepatic steatosis in an in vitro model of NAFLD.PLoS One. 2024 Apr 17;19(4):e0297572. doi: 10.1371/journal.pone.0297572. eCollection 2024. PLoS One. 2024. PMID: 38630788 Free PMC article.
-
A UPLC-MS/MS method for simultaneous determination of arachidonic acid, stearic acid, and related endocannabinoids in human plasma.Heliyon. 2024 Mar 21;10(7):e28467. doi: 10.1016/j.heliyon.2024.e28467. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38560270 Free PMC article.
-
Endoplasmic Reticulum Protein TXNDC5 Interacts with PRDX6 and HSPA9 to Regulate Glutathione Metabolism and Lipid Peroxidation in the Hepatic AML12 Cell Line.Int J Mol Sci. 2023 Dec 5;24(24):17131. doi: 10.3390/ijms242417131. Int J Mol Sci. 2023. PMID: 38138960 Free PMC article.
-
Korean red ginseng formula attenuates non-alcoholic fatty liver disease in oleic acid-induced HepG2 cells and high-fat diet-induced rats.Heliyon. 2023 Nov 4;9(11):e21846. doi: 10.1016/j.heliyon.2023.e21846. eCollection 2023 Nov. Heliyon. 2023. PMID: 38027623 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
